Top 50 Biotech Startup Investors in Australia (October 2023)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Uniseed Ventures
VC Fund
|
21 | Australia, United States, United Kingdom | Series A, Seed | Biotechnology, Manufacturing, Health Care | $364k–$6.4M |
|
Brandon Capital Partners
VC Fund
|
15 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $642k–$25M |
|
Medical Research Commercialisation Fund (MRCF)
VC Fund
|
11 | Australia, United States, United Kingdom | Series A, Seed, Series B | Biotechnology, Health Care, Medical | $1.3M–$13M |
|
Stoic VC
VC Fund
|
7 | Australia, United States, United Kingdom | Seed, Series A | Biotechnology, Medical, Health Care | |
|
OneVentures
VC Fund
|
6 | Australia, United States, Israel | Series A, Debt Financing | Software, Health Care, Information Technology | $1.5M–$20M |
|
Artesian VC
VC Fund
|
5 | Australia, United States, Hong Kong | Seed, Series A, Pre-Seed | Software, Artificial Intelligence, Information Technology | $70k–$12M |
|
Melbourne Angels
VC Fund
|
5 | Australia, United States, New Zealand | Angel, Seed | Biotechnology, Information Technology, Manufacturing | $32k–$893k |
|
Main Sequence Ventures
VC Fund
|
4 | Australia, United States, Philippines | Series A, Seed, Series B | Software, Artificial Intelligence, Information Technology | $1.3M–$49M |
|
Clean Energy Finance Corporation
VC Fund
|
3 | Australia, United States | Series B, Series A, Seed | Energy, Solar, Renewable Energy | $2.5M–$19M |
|
Horizons Ventures
VC Fund
|
3 | United States, United Kingdom, Canada | Series A, Series B, Seed | Biotechnology, Artificial Intelligence, Software | $750k–$70M |
|
Yuuwa Capital
VC Fund
|
3 | Australia | Series A, Seed, Series B | Biotechnology, Analytics, Health Care | $128k–$6.1M |
|
Starfish Ventures
VC Fund
|
3 | United States, Australia, Philippines | Series A, Series B | Software, Enterprise Software, Information Technology | $642k–$14M |
|
Sydney Angels
VC Fund
|
2 | Australia, United States | Seed, Angel | Software, SaaS, Apps | $161k–$895k |
|
Global Health Investment Fund (GHIF)
VC Fund
|
2 | United States, India, Austria | Series B, Series C | Health Care, Biotechnology, Medical Device | $4.5M–$17M |
|
Brisbane Angels
VC Fund
|
2 | Australia, United States, New Zealand | Seed, Angel | Software, Information Technology, Artificial Intelligence | $321k–$835k |
|
Lowercarbon Capital
VC Fund
|
2 | United States, United Kingdom, France | Seed, Series A | Biotechnology, Renewable Energy, Energy | $2.7M–$50M |
|
South Australian Venture Capital Fund
VC Fund
|
2 | Australia | Series A, Series B | Health Care, Biotechnology, SaaS | |
|
Allan Moss
Angel
|
2 | Australia, United States, The Netherlands | Series A, Seed | Health Care, Medical Device, Biotechnology | |
|
Vectr
VC Fund
|
2 | United States, Hong Kong, Singapore | Seed, Series A, Pre-Seed | FinTech, Artificial Intelligence, Financial Services | $425k–$35M |
|
BridgeLane Capital
VC Fund
|
2 | Australia, Germany | Seed, Series B | Software, Financial Services, Health Care | $642k–$13M |
|
Folklore Ventures
VC Fund
|
2 | Australia, New Zealand, United States | Seed, Series A | Software, Apps, Information Technology | $250k–$15M |
|
Grok Ventures
VC Fund
|
2 | Australia, United States, Hong Kong | Series A, Series B, Seed | Renewable Energy, Software, Internet of Things | $1M–$465M |
|
Possible Ventures
VC Fund
|
2 | Germany, Australia, United States | Seed, Pre-Seed, Series A | Software, Information Technology, Biotechnology | $350k–$43M |
|
HealthCare Ventures
VC Fund
|
1 | United States, Australia, United Kingdom | Series B, Series A, Series C | Biotechnology, Health Care, Pharmaceutical | $4.4M–$50M |
|
Mercia Fund Managers
VC Fund
|
1 | United Kingdom, United States, Australia | Seed, Series A | Software, Health Care, Science/Engineering | $184k–$21M |
|
Southern Cross Venture Partners
VC Fund
|
1 | United States, Australia, Singapore | Series B, Series A | Software, Manufacturing, Renewable Energy | $2M–$15M |
|
CP Ventures
VC Fund
|
1 | Australia, United States, India | Seed, Pre-Seed, Series A | Software, Artificial Intelligence, Machine Learning | $364k–$12M |
|
Agronomics
VC Fund
|
1 | United States, Finland, Australia | Seed, Series A, Series B | Biotechnology, Food and Beverage, Food Processing | $500k–$20M |
|
Grand Challenges Canada
VC Fund
|
1 | Canada, United States, Australia | Grant, Seed, Debt Financing | Health Care, Medical Device, Biotechnology | $100k–$3.3M |
|
Ellerston Capital
VC Fund
|
1 | Australia, Hong Kong, United Kingdom | Seed, Series A | Software, Information Technology, E-Commerce | $850k–$16M |
|
Northpond Ventures
VC Fund
|
1 | United States, United Kingdom, Australia | Series A, Series B, Series C | Science/Engineering, Biotechnology, Health Care | $9M–$93M |
|
Playford Capital
VC Fund
|
1 | Australia | Series A, Series B | Health Care, Biotechnology, Medical Device | |
|
Acre Venture Partners
VC Fund
|
1 | United States, Brazil, Argentina | Series A, Series B, Series C | Food/Beverage, Gaming, Science/Engineering | $10M–$89M |
|
Right Click Capital
VC Fund
|
1 | Australia, Singapore, United States | Seed, Series A | Software, IT, Data and Analytics | $64k–$15M |
|
HESTA
VC Fund
|
1 | Australia | Series A, Series B, Series C | Sensor, Medical, Aerospace | |
|
AbbVie Biotech Ventures
VC Fund
|
1 | United States, China, Italy | Series A, Series B, Series C | Biotechnology, Science/Engineering, Health Care | $6M–$100M |
|
Alloy Ventures
VC Fund
|
1 | United States, Canada, Australia | Series C, Series B, Series D | Software, Science/Engineering, Hardware | $4.9M–$50M |
|
Terra Rossa Capital
VC Fund
|
1 | Australia | Series A, Series B | Health Care, Biotechnology, Medical Device | |
|
Nanyang Ventures
VC Fund
|
1 | Australia | Series A | Health Care, Biotechnology, Science/Engineering | |
|
CaraMed Capital
VC Fund
|
1 | Australia | Seed | Biotechnology | |
|
Powerhouse Ventures
VC Fund
|
1 | United States, Australia, United Kingdom | Seed, Series A, Pre-Seed | Software, Energy, Solar | $726k–$30M |
|
Transition Level Investments
VC Fund
|
1 | Australia, United States | Seed, Pre-Seed, Series A | Software, Financial, IT | $60k–$2.4M |
| Alta Partners | 1 | Series C, Series B | Biotechnology, Health Care, Science/Engineering | $10M–$109M | |
|
Accelerating Commercialisation - AusIndustry
VC Fund
|
1 | Australia | Grant, Pre-Seed | Software, Mining, Hardware | |
| GBS Ventures | 1 | Series A, Series C, Series B | Health Care, Biotechnology, Science/Engineering | $2.1M–$55M | |
|
Closed Loop Partners
VC Fund
|
1 | United States, United Kingdom, Chile | Series A, Seed | Recycling, Supply Chain Management, Artificial Intelligence | $3.2M–$16M |
|
Catherine Lacavera
Angel
|
1 | Canada, Australia | Seed, Pre-Seed | Medical, Health Care, Biotechnology | |
|
Daniel Petre
Angel
|
1 | Australia | Seed, Pre-Seed, Series A | SaaS, Software, Banking | |
|
Dexcom Ventures
VC Fund
|
1 | Australia | Sensor, Medical, Wearables | ||
|
Maropost Ventures
VC Fund
|
1 | United States, Australia, Sweden | Seed, Series A, Secondary Market | Science/Engineering, Commerce/Shopping, Data and Analytics | $1.1M–$10M |
| Access all 50 investors in Australia Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Uniseed was established in October 2000 as a $20 million joint venture between the University of Melbourne (UM) and the University of Queensland (UQ). This proof of concept fund (Fund-1) operated with significant input and support from the commercialization offices of the two universities (UniQuest and Melbourne Ventures Limited), with staff ofthese organizations making up the majority of the Investment Committee and leading due diligence and management of most investment opportunities. Over 20 investments, typically of $250,000 - $500,000 were made from this fund.A new $40 million venture fund (Fund-2) ran from 2005-15, with the addition of a third leading university, the University of New South Wales, and a major private institutional investor, the Westscheme superannuation fund. The founding universities (UQ & UM) also committed further funds. Australian Super took over Westscheme's essets and commitments in July 2011.With the start of Fund-2, an independent management team was established, consisting of the CEO and three Investment Managers; one at each university catchment. The Investment Committee was restructured, with dedicated committees established for biotechnology or other technologies. The nominal investment limit was increased to $2.5 million to allow participation in follow-on funding rounds so as to preserve Uniseed's equity position.On 1 November 2015, Uniseed started its third and largest fund (Fund-3) with the addition of the University of Sydney and the CSIRO to the Universities of Queensland, Melbourne and NSW. This followed three high profile exits in the preceding 14 months (Fibrotech; Spinifex & Hatchtech). Each of the five partners committed $10 million over 10 years to the new fund (total fund $50 million).Uniseed’s partner research organisations spent nearly $4 billion on research, making up over 40% of the total research spend at 67 research organisations in Australia. Together, these organisations accounted for nearly 500 invention disclosures (34% of total) and 500 new registered IP rights filed (45% of total) over the same period(2013 National Survey of Research Commercialisation). Unlike private venture capital funds, Uniseed is dedicated to the needs of its research partners, and committed to servicing them consistently over the long term, irrespective of the short term conditions in external capital markets. It works in very close partnership with the research partner commercialisation companies and staff, providing a valuable adjunct to the capabilities these companies and staff provide. They in turn provide a best-practice commercialisation service tailored to their respective organisations. These companies are able to leverage to great effect the scale of operation and expertise of the Uniseed network.The fund is run with commercial discipline, ensuring independence and financial rigor in its investment decision-making processes. Success is measured by a balance of return on investment (including the flow of funds for research to further the commercialisation of intellectual property generated within the research partner catchments), the establishment of viable start-up companies, the generation of research income for research partners and the improvement of partner commercialisation processes.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing, Health Care
- Stage:Series A, Seed
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 56
- Round size: Seed $364k–$2M; Series A $1.3M–$6.4M
- Lead/follow: 13% lead, 87% follow
- Last fund: May invest from a new fund soon — raised $13M in 2017
Portfolio highlights
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Morse Micro — Smarter, farther, better. Meet the latest Wi-Fi, HaLow, 802.11ah. 10X FARTHER>1Km range, 100x area, 1000x volume 10X EFFICIENCYMulti-year on a single
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Brandon Capital invests in the most promising biomedical opportunities that have the potential to improve the lives of patients.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 39
- Round size: Seed $642k–$6.4M; Series A $4M–$20M; Series B $5M–$25M
- Lead/follow: 31% lead, 69% follow
- Last fund: May invest from a new fund soon — raised $210M in 2019
Portfolio highlights
- CatalYm — Catalym develops antibodies against a placental factor which is overexpressed by various tumour types.
- Entact Bio — Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function. It was founded by a team with deep roots in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development. The company's proprietary EncompassTM platform was designed tocreate enhancement-targeting chimeric (ENTACTM) medicines. ENTACs take advantage of DUBs' ability to regulate proteins.
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
Medical Research Commercialisation Fund (MRCF) provides dedicated, investment funding to support the commercialisation of early-stage medical research discoveries that originate from its member institutes. The collaborative nature of the MRCF seeks to foster best practice in the commercialisation of medical innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 25
- Round size: Series A $1.3M–$13M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Glyscend — Glyscend develops a revolutionary approach to treating type 2 diabetes. The company began with the insight that bariatric surgery can lead to the immediate remission of the disease, and has since been engaged in the development of a non-invasive approach which will act on the same mechanism as surgery but fit within the current care pathway. Thecompany's technology is an orally ingestible intestinal coating that prevents the stimulation of duodenal mucosa and inhibits key neurohormonal pathways in the proximal gut. Glyscend is devoted to providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. Meanwhile, the company aims to provide endocrinologists and primary care physicians with the innovative tools they need to treat the disease instead of merely managing it. It was founded in 2014 by co-founders Ashish Nimgaonkar, Michael Parlato, and Pratik Patel.
- Currus Biologics — Currus Biologics is a biotechnology company that develop CAR-T cell therapies for the treatment of solid tumour cancers.
- Azura Ophthalmics — Azura Ophthalmics is a clinical-stage company that develops an innovative portfolio of compounds to advance treatments for MGD, the leading cause of DED. By targeting the root cause of MGD, Azura brings the promise of improved health and well-being to millions of people worldwide who suffer from MGD and other ocular surface diseases where treatmentoptions are currently lacking. Azura is underpinned by an experienced management team with an established track record of successfully developing and commercializing novel treatments for ocular surface diseases. The company headquartered in Tel Aviv-Yafo, Israel with operations in Australia and the U.S.
Stoic VC is an early-stage venture fund backing founders at the forefront of University Innovation. We partner with Uniseed to accelerate the commercialisation of university research across the ANZ.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Seed, Series A
- Geography: Australia, United States, United Kingdom
Investor stats
- Total investments: 20
- Lead/follow: 5% lead, 95% follow
Portfolio highlights
- Ena Respiratory — Ena Respiratory is a biotechnology company seeking to transform the treatment and prevention of respiratory infections and the effectiveness of vaccines.Ena Respiratory novel, synthetic Toll-like receptor 2 (TLR2) receptor agonists have been shown to activate the innate immune system in the respiratory tract and prevent viral and bacterialdissemination to the lungs.
- BioScout — Welcome to BioScout, your partner in revolutionizing the agriculture industry with cutting-edge automated disease detection technology for crop growers and viticulture. Our high-level introduction and detailed insights into our innovative solutions, exceptional collaborations, and dedicated team make it easy to understand WHO we are, WHAT we do, and HOW we do it. Stay updated with valuable resources, customer portal, and regular content via our blog. Contact us today to collaborate and optimize your farm's productivity and sustainability.
- Lenexa Medical — Lenexa Medical is driving towards better healthcare solutions for patients in hospital and aged-care by preventing pressure injuries and empowering clinicans.
OneVentures is one of Australia’s leading venture capital firms, with over $330M in funds under management. But they do more than invest. They take companies to that all important next stage, by actively shaping their future. They apply their years of international experience, operational and executional expertise to accelerate the growth of theirportfolio companies. A global growth focus drives their investment selection with their current portfolio including companies with truly innovative products tackling multi-billion-dollar problems, from needle-free vaccinations to virtual communications to adaptive e-learning.
Show more...Investment focus
- Industry: Software, Health Care, Information Technology
- Stage:Series A, Debt Financing
- Geography: Australia, United States, Israel
Investor stats
- Total investments: 64
- Round size: Series A $1.5M–$20M; Debt Financing $1.8M–$4M
- Lead/follow: 47% lead, 53% follow
- Last fund: Likely still investing — raised $128M in 2022
Portfolio highlights
- Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
- BiVACOR — BiVACOR is a privately held company founded in 2008. Their staff includes world-class engineers, medical specialists, and business executives, who are diligently working to advance this ground-breaking technology. Together, they have established a strong collaborative network that extends both nationally and internationally. Their worldheadquarters is located in Houston, Texas, USA, and their international office is in Brisbane, Australia.
- ImmVirX — ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect.
Artesian Capital Management is an alternative investments management company, which was spun out of ANZ Banking Group's capital markets business in 2004, with backing from ANZ Private Equity. Artesian's founding partners, purchased ANZ's stake in 2005. The company has subsequently been fully owned by partners and staff. Since 2004,Artesian has managed specialised funds focused on credit arbitrage and relative-value strategies across global financial markets. In 2008, while continuing to manage credit relative value investment strategies from its New York, London and Singapore offices, Artesian began to make principal investments in seed/early-stage ventures from its offices in Sydney, Melbourne and Shanghai. In 2011, Artesian launched the first of its early stage venture capital funds and now manages AUD +255m. Artesian's VC strategy is to partner with best of breed accelerators, incubators, angel groups and university programs. In 2017, Artesian launched its China VC Fund with a USD 50m cornerstone investment industry super fund Hostplus. Artesian will soon launch a Southeast Asia VC Fund.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 172
- Round size: Seed $96k–$2.4M; Pre-Seed $70k–$1.5M; Series A $3.3M–$12M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — fund raised in 2021
Portfolio highlights
- ZoomAgri — ZOOMAGRI provides an assessment of agricultural commodities to all participants of Agri supply chain via AI, computer vision and IoT.
- Supplynote — End-to-end supply chain management tool to track inventory, orders, payments and suppliers online
- Navi Medical Technologies — Navi Medical Technologies is a medical device development company.
Melbourne Angels was formed in Melbourne, Australia in early 2007. Melbourne Angels is the leading group of private investors in Victoria who actively invest in early stage and growth technology companies.The group has a strong and experienced core of members that generate deal flow, are experienced in evaluation of business propositions and actas mentors for the other members and the entrepreneurs. The members vary in age, gender, ethnicity, profession and type of experience. All members have experience of success at being entrepreneurial.This award winning group is consistently one of the most active startup investors in the country.
Show more...Investment focus
- Industry: Biotechnology, Information Technology, Manufacturing
- Stage:Angel, Seed
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 34
- Round size: Seed $32k–$771k; Angel $601k–$893k
- Lead/follow: 56% lead, 44% follow
Portfolio highlights
- Tayble — Spend more time enjoying your food and less time waiting.We hate waiting...For anything...And food and drinks are no exception!If your hobbies include:- Waiting in line - Calling out to a waiter - Watching the kettle boil - Calculating your split of the billPLEASE DO NOT DOWNLOAD THIS APP... YOU'LL HATE IT!But if you're likeus...And want your food and drinks ready exactly when you are...Or to leave a restaurant without worrying about your bill...Then step right up, this bad boy's for you!With Tayble, you’ll never have to flag down a waiter... EVER!Simply order from your "Tayble"Or before you even arrive...Leave the rest to us and the 1,000's of minions in the cloud that keep this all running!You’ll be left asking where has this been all my life, guaranteed!*(Definitely not a real guarantee)
- Insite AI — We create predictability for consumer brands in the unpredictable world of retail. Game-changing technology that attacks consumer brands' hardest problems.
- Apop Imaging — Apop Imaging develops and commercialises novel imaging, diagnostic and therapeutic tools to improve patient outcomes based on our proprietary calcitonin receptor antibody technology.
We work with inventors who are building something hard from their unique expertise in science. These inventors are building the industries that will thrive for the decades to come. We have a unique working model to accelerate a company's pathway to scale.
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Information Technology
- Stage:Series A, Seed, Series B
- Geography: Australia, United States, Philippines
Investor stats
- Total investments: 65
- Round size: Seed $1.3M–$6M; Series A $3.8M–$22M; Series B $12M–$49M
- Lead/follow: 54% lead, 46% follow
- Last fund: May invest from a new fund soon — raised $161M in 2021
Portfolio highlights
- Endua — Endua is building the next generation of clean energy deep storage to power communities, remote industries and off-grid infrastructure at the flick of a switch - all day and night
- Jdoodle — JDoodle is an Online Compiler, Editor, IDE for Java, C, C++, PHP, Perl, Python, Ruby and many more. You can run your programs on the fly online, and you can save and share them with others. Quick and Easy way to compile and run programs online.
- Number 8 bio — Number 8 bio objective is to decarbonize agriculture while feeding the world's rising population. This can be accomplished by harnessing the power of trillions of carbon-hungry bacteria that feed on harmful greenhouse gases and turn them into profitable animal feeds.
The Clean Energy Finance Corporation invests, applying commercial rigour, to increase the flow of finance into the clean energy sector. Their mission is to accelerate Australia's transformation towards a more competitive economy in a carbon constrained world, by acting as a catalyst to increase investment in emissions reduction. They do thisthrough an investment strategy focused on cleaner power solutions, including large and small-scale solar, wind and bioenergy; and a better built environment, with investments to drive more energy efficient property, vehicles, infrastructure and industry. The CEFC also invests with co-financiers to develop new sources of capital for the clean energy sector, including climate bonds, equity funds, aggregation facilities and other financial solutions. The CEFC operates under the Clean Energy Finance Corporation Act 2012.
Show more...Investment focus
- Industry: Energy, Solar, Renewable Energy
- Stage:Series B, Series A, Seed
- Geography: Australia, United States
Investor stats
- Total investments: 41
- Round size: Seed $6M–$16M; Series A $2.5M–$13M; Series B $5M–$19M
- Lead/follow: 47% lead, 53% follow
- Last fund: May invest from a new fund soon — last raise in 2018
Portfolio highlights
- Infradebt — Infradebt t is a specialist fund manager providing clients with direct access to infrastructure private debt markets.
- Gunn Agri Partners — Gunn Agri Partners is an agricultural investment company that offers advice and services for acquisitions, asset, farm, and fund management.
- HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
Investing in the deep science and technology that can propel humanity towards a radically better future.
Show more...Investment focus
- Industry: Biotechnology, Artificial Intelligence, Software
- Stage:Series A, Series B, Seed
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 216
- Round size: Seed $750k–$11M; Series A $6M–$30M; Series B $8M–$70M
- Lead/follow: 45% lead, 55% follow
Portfolio highlights
- BioLoomics — BioLoomics is a preclinical stage biotechnology company that uses evolution in a microscope to develop drug discovery tools and protein drugs. Our VariVolve platform tests millions of protein designs for a targeted activity in hours, enabling efficient mining of the vast chemical space of protein designs. A strong advantage of our approach is theuse of whole intact cells as test vessels that capture complex drug behavior not attainable in conventional assays.
- Erthos — erthos is a producer of biodegradable packaging materials intended to replace traditional polystyrene and polypropylene inputs.
- ZeroAvia — ZeroAvia is producing the world's first practical zero emission aviation powertrain, initially targeting 20-seat airplanes to start replacing dirty jet fuel in regional transport
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Yuuwa Capital is a $40M early-stage venture capital firm based in Perth, Western Australia. They are actively seeking outstanding investment opportunities where Yuuwa can provide both capital and expertise to help founders, management and early investors to turn good ideas into great companies.
Show more...Investment focus
- Industry: Biotechnology, Analytics, Health Care
- Stage:Series A, Seed, Series B
- Geography: Australia
Investor stats
- Total investments: 16
- Round size: Seed $128k–$771k; Series A $964k–$4.2M; Series B $2.6M–$6.1M
- Lead/follow: 63% lead, 37% follow
Portfolio highlights
- Nexgen Plants Pty Limited — Healthy plants, healthy people, living planet. Nexgen develop's plants for future generations that will improve the environment and health of future generations.
- icetana — icetana Motion Intelligence dramatically improves the active monitoring of security surveillance networks, with AI video anomaly detection and video analytics.
- Agworld Pty Ltd — Agworld Farm Management software allows you to collect data at all levels and enables you to extract maximum value from this data; optimising profitability. The Agworld ecosystem is utilised by growers, agronomists and service providers on farms across the world.
Starfish Ventures is an Australian venture capital firm focused on information technology, life sciences, and clean technology companies.
Show more...Investment focus
- Industry: Software, Enterprise Software, Information Technology
- Stage:Series A, Series B
- Geography: United States, Australia, Philippines
Investor stats
- Total investments: 51
- Round size: Series A $642k–$6.6M; Series B $2.5M–$14M
- Lead/follow: 53% lead, 47% follow
- Last fund: May invest from a new fund soon — raised $119M in 2008
Portfolio highlights
- Aktana — Build stronger relationships with HCPs using Aktana's artificial intelligence (AI) platform for life sciences to optimize omnichannel engagement.
- DesignCrowd — Crowdsourced logo, freelance graphic and web design at DesignCrowd. 1,136,169 freelance designers compete to create amazing designs for your business. Start Today!
- Marani — Marani Health is developing a prenatal care platform which includes a wearable, textile-based product to measure key vital statistics of women and their developing fetus, for use during pregnancy, labor & delivery. The products utilize Artificial Intelligence to better assess health & wellness during pregnancy, labor & delivery. Maraniis collaborating with key partners including The Mayo Clinic.
Sydney Angels is a not-for-profit angel investment membership organisation. Since our establishment in 2008, they have stayed true to our mission of supporting the early-stage ecosystem by running processes and events that connect our investing members with promising early-stage companiesThey believe that encouraging smart investment in startupcompanies will benefit both our members’ portfolios and Australia’s emergent innovation economy.They see this as the ultimate win-win situation. Sydney Angels is led by an elected committee of ten volunteers who meet weekly. It is supported by an operations manager and alliance partners.
Show more...Investment focus
- Industry: Software, SaaS, Apps
- Stage:Seed, Angel
- Geography: Australia, United States
Investor stats
- Total investments: 42
- Round size: Seed $161k–$895k; Angel $330k–$890k
- Lead/follow: 60% lead, 40% follow
- Last fund: May invest from a new fund soon — last raise in 2016
Portfolio highlights
- Kapiche — Instant insights. No set up or coding. The Kapiche feedback analytics platform helps you ingest and analyze mountains of customer feedback in minutes.
- Remi AI — A.I-Powered Demand Forecasting, Supply Chain AI, & Price Optimisation | Remi AI
- Trendspek — Trendspek is the drone data solution asset managers use to make empowered decisions and ensure absolute asset knowledge. Conduct complete visual inspections from any web browser. Extract detailed insights without a site visit. Use powerful tools to analyse the structure and build a complete picture of asset condition. Enhance predictive maintenanceby closely monitoring trends. View different models side by side to observe important differences. Refine your understanding of an ever-changing asset.
The Global Health Investment Fund (GHIF) is a $108 million social impact investment fund designed to provide financing to advance the development of drugs, vaccines, diagnostics and other interventions against diseases that disproportionately burden low- and middle-income countries. GHIF supports late-stage innovations for public health challengessuch as malaria, pre-eclampsia, cholera, HIV and river blindness, with an emphasis on infectious diseases and maternal/infant health issues that cause significant morbidity and mortality in resource-limited settings. GHIF may also make investments that improve or expand access to existing products—such as developing pediatric formulations of approved therapeutics or improving the stability of widely-used global health vaccines.As an investment fund with a limited time-horizon, GHIF seeks opportunities that have a high probability of successful commercialization within two or three years. Products with “dual market” potential are of greatest interest; i.e., those that will have a clear impact on public health in developing countries but also have value in high-income countries. High-volume / low-margin products, such as essential vaccines, are also of significant interest.GHIF employs a range of investment structures including mezzanine debt, convertible debt, preferred equity and project financing with an average investment target of approximately $10 million per project. Each GHIF project must advance the Fund’s social impact objectives and demonstrate the ability to achieve commercial success.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series B, Series C
- Geography: United States, India, Austria
Investor stats
- Total investments: 18
- Round size: Series B $7.5M–$17M; Series C $4.5M–$14M
- Lead/follow: 39% lead, 61% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Monod Bio — Monod Bio l Simple. Powerful. Biosensors for Medicine & Biotech.
- CXL Ophthalmics — CXLO is developing a minimally invasive treatment for an ectatic corneal disease that can bring early intervention to millions of patients globally.
- Endpoint Health — Endpoint Health is a precision-first therapeutics company. By rewriting the molecule-first drug development model, we aim to deliver precision therapies that have the potential to improve outcomes for patients with immune-driven illnesses.
Formed in late 2006, the Brisbane Angels Pty Ltd is a large group of private investors who actively invest in early stage technology companies, usually in South East Queensland, Australia. The members are typically active or semi-retired former senior business executives, who apart from financial input can provide much needed value adding toinvestee companies through hands-on management experience and high level business networks.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Angel
- Geography: Australia, United States, New Zealand
Investor stats
- Total investments: 28
- Round size: Seed $347k–$835k; Angel $321k–$601k
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Tribu — Here at tribu we aim to make running an MSP stress-free and simple. Remove complexity and repetitive shackles to give you the freedom in business so that you can have freedom in life.
- Avasa — Avasa is a medical device company. It helps to improve surgical procedures by developing novel implantable devices.
- One Key Access — One Key Access is an interface to the world of couriers to enable 24/7 frictionless deliveries.
Lowercarbon Capital backs kickass companies slashing CO2 emissions, sucking carbon out of the sky, and buying us time to unf**k the planet.
Show more...Investment focus
- Industry: Biotechnology, Renewable Energy, Energy
- Stage:Seed, Series A
- Geography: United States, United Kingdom, France
Investor stats
- Total investments: 102
- Round size: Seed $2.7M–$11M; Series A $6.5M–$50M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Dioxycle — Dioxycle is develop electrolyser solutions for carbon dioxide emissions.
- Isometric — Isometric is a carbon removal registry and science platform
- Arc Boats — Arc manufactures and sells high-performance electric boats for watersports.
South Australian Venture Capital Fund - helping build dynamic and innovative South Australian startups / scaleups and accelerate their growth to a national and global scale.
Show more...Investment focus
- Industry: Health Care, Biotechnology, SaaS
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 4
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Lumary — Simplify Your Care Management Optimise Your Organisation Create Better Wellbeing
- BiomeBank — BiomeBank is a clinical stage biotechnology company with a mission to treat our microbiome and prevent disease by restoring gut microbial ecology.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
Allan Moss acts an adviser to Anchorage’s Investment Committee. Currently Principal of Allan Moss Investments, a private investment company, Allan retired from the role of Managing Director and Chief Executive Officer of Macquarie Group in May 2008. He was with Macquarie Group for 31 years and served as CEO from 1993 to his retirement in2008. He was also a non- executive director of CSR Ltd from 1996 to 2001.Allan graduated from Sydney University in Arts with a major in Economics and in Laws with Honours. He is also a graduate of Harvard University with a Masters Degree in Business Administration with High Distinction. Allan has received numerous industry awards and recognitions. He was twice named by Barron’s Magazine as one of the 30 most respected CEOs in the world (2006, 2007). He was appointed an Officer of the Order of Australia in 2005.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Series A, Seed
- Geography: Australia, United States, The Netherlands
Investor stats
- Total investments: 9
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Skykraft — Skykraft is an Australian space services firm that specializes in smallsat constellation design, production, and operation.
- Ferronova — Ferronova is a medical device company that offers imaging and surgery products.
- Invert Robotics — Invert Robotics develops robotic NDT inspection technologies for the maintenance of industrial equipment in the food and beverage, pharmaceutical, and oil and gas industries. Invert Robotics highly skilled team of engineers have developed a world leading modular inspection platform suitable for use across a range of industries and applications.
Vectr is a venture firm based in Hong Kong. They combine investment, creation and growth to deliver game-changing impact to teams ready to tackle global issues, transform industries and improve the lives of millions.That combines capital, creation and partnership to deliver game-changing impact. We strive to be the ideal partner for founders thatare building transformation products and looking to expand their businesses into asia.
Show more...Investment focus
- Industry: FinTech, Artificial Intelligence, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Hong Kong, Singapore
Investor stats
- Total investments: 72
- Round size: Seed $425k–$4M; Series A $1M–$35M
- Lead/follow: 19% lead, 81% follow
Portfolio highlights
- Percent — Unlock private credit investments with Percent. Access alternative investments on the platform powering the future of private markets.
- Micro Connect — Micro Connect provides market infrastructure, fintech, and platform development.
- MasterExchange — Trading platform for music rights leveraging emerging technology to create friction free and compliant investment opportunities to everyone.
The BridgeLane Group is a privately-owned asset management firm specialising in the agricultural, real estate and innovation sectors. A significant global player in agriculture with a multi-decade record in large scale farming, the Group has a proud history in residential property development, comme
Show more...Investment focus
- Industry: Software, Financial Services, Health Care
- Stage:Seed, Series B
- Geography: Australia, Germany
Investor stats
- Total investments: 16
- Round size: Seed $642k–$2M; Series B $5M–$13M
- Lead/follow: 38% lead, 62% follow
Portfolio highlights
- Agerris — Agerris is a field robotics and AI start-up for the agriculture industry, based on technology created at the Australian Centre for Field Robotics, the University of Sydney, where they have been developing air and ground robotic solutions for the agriculture industry since 2005.
- Sprout Stack —
- Evrima Technologies — Our clinical trial recruitment and management services put participants first. Trusted, timely clinical trial results are a good thing - for everybody.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Folklore is a team of investors, founders, and builders committed to supporting Australian and New Zealand tech founders. We are a first cheque to forever investment firm, and we believe in the power of founder vision and the potential of teams, right from the start.
Show more...Investment focus
- Industry: Software, Apps, Information Technology
- Stage:Seed, Series A
- Geography: Australia, New Zealand, United States
Investor stats
- Total investments: 31
- Round size: Seed $250k–$4.8M; Series A $500k–$15M
- Lead/follow: 61% lead, 39% follow
- Last fund: May invest from a new fund soon — raised $40M in 2017
Portfolio highlights
- Swoop Aero — Transforming how the world moves by making access to the skies seamless.
- HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
- SimConverse — SimConverse is a simulation platform that uses generative AI to play the role of any patient, colleague or casualty.
Grok Ventures is a private investment company. They back world-class teams solving big problems to shape a better future. They invest in fast growing technology-enabled businesses.
Show more...Investment focus
- Industry: Renewable Energy, Software, Internet of Things
- Stage:Series A, Series B, Seed
- Geography: Australia, United States, Hong Kong
Investor stats
- Total investments: 43
- Round size: Seed $1M–$7.1M; Series A $2.6M–$75M; Series B $100M–$465M
- Lead/follow: 33% lead, 67% follow
Portfolio highlights
- Lydian — Lydian aims to accelerate the decarbonization of the chemical industry by electrifying the chemical production process. Founded in 2021 by Branko Zugic, Lydian is headquartered in
- Loam Bio — Loam Bio is developing tech that allows for crops to be inoculated with symbiotic micro-organisms.
- Fleet Space Technologies — Fleet is an agile, next generation connectivity company. Our mission is to Connect Everything using cutting-edge communications and space technologies to maximise the resource efficiency of human civilisation and enable the next industrial revolution with our free, ubiquitous connectivity platform.
Possible Ventures backs ambitious teams building frontier technology to positively impact society. We invest globally in the early stages, actively supporting founders via our collective of global entrepreneurs.
Show more...Investment focus
- Industry: Software, Information Technology, Biotechnology
- Stage:Seed, Pre-Seed, Series A
- Geography: Germany, Australia, United States
Investor stats
- Total investments: 117
- Round size: Seed $2M–$7M; Pre-Seed $350k–$2.5M; Series A $6.9M–$43M
- Lead/follow: 3% lead, 97% follow
Portfolio highlights
- Automata — Automata is a deep-tech company that creates products that empower people to automate physical work. The company's product, Eva, is a lightweight and affordable robot arm built for professionals in a production line, in a lab, a home workshop or even in a classroom. People don't need to be technical experts to communicate with robots. Theweb-based software platform can be programmed by anyone, anywhere, any time, from any device, making it easy to reconfigure for a wide range of different tasks.Automata was founded on 2015 and is headquartered in London, England.
- Eden Brew — Eden Brew is a ground-breaking new way to enjoy dairy products sustainably and nutritiously.
- Pow.bio — Pow.bio provides fermentation services for synthetic biology.
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Series B, Series A, Series C
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 102
- Round size: Series A $4.4M–$37M; Series B $10M–$50M; Series C $10M–$44M
- Lead/follow: 18% lead, 82% follow
- Last fund: May invest from a new fund soon — last raise in 2010
Portfolio highlights
- Colorescience — Know Better Skin with Colorescience. From mineral sunscreen to clinical skincare products, achieve a clear, even complexion and protect your skin from the damaging effects of the sun and environmental aggressors such as pollution. Shop Now!
- Leap Therapeutics — Leap Therapeutics, Inc., a clinical-stage biopharmaceutical company, is engaged in acquiring and developing novel therapeutics. The company focus is to identify translational-stage molecules in the areas of cell signaling and immuno-oncology.
- Proteostasis Therapeutics — Proteostasis Therapeutics is discovering and developing novel small molecule therapeutics designed to control the body's protein homeostasis, or Proteostasis Network. The Proteostasis Network maintains the body's natural balance of proteins to protect us from numerous diseases. These novel therapies, or Proteostasis Regulators, aredesigned to treat multiple genetic and degenerative disorders associated with deficiencies of the Proteostasis Network, such as emphysema, type II diabetes, Alzheimer's Disease and Huntington's Disease.
Mercia Asset Management providing equity and debt to regional businesses with growth ambition. We are your capital partners from scale-up to exit.
Show more...Investment focus
- Industry: Software, Health Care, Science/Engineering
- Stage:Seed, Series A
- Geography: United Kingdom, United States, Australia
Investor stats
- Total investments: 112
- Round size: Seed $184k–$1.8M; Series A $1.2M–$21M
- Lead/follow: 69% lead, 31% follow
- Last fund: May invest from a new fund soon — last raise in 2013
Portfolio highlights
- Turbine — Turbine builds a platform to understand the inner mechanisms of cancer, enabling the discovery of novel protein targets, precision biomarkers, and better translation to patients. Turbine uses its proprietary Simulated Cell technology in combination with Artificial Intelligence to build a faster and deeper biological understanding of therapeutictargets or indications, untangling the complexity of cancer.
- Log my Care — Log My Care is a free electronic care planning and care management system for home care providers. Its platform provides a to-do log, which is shared with care employees to let them know their tasks and gives printable reports about activity performance that enable managers to operate care institutes in a hassle-free way.
- Role Mapper Technologies — Automate and transform how you design and manage job descriptions across your organisation. Hire, retain and grow an inclusive and diverse workforce with AI powered Intelligent Job Design.
Southern Cross Venture Partners was launched in 2006 by veteran venture capitalists who have managed and operated companies themselves. Southern Cross Venture Partners assist early stage technology companies that demonstrate the potential for exceptional growth and market leadership build significant businesses. The founding principle of SouthernCross is partnership -- they are passionately committed to doing everything they can to help their portfolio companies succeed. Their team has a strong record of utilizing their start-up and management experience, industry knowledge, network of business/customer relationships, and recruiting skills to assist in building significant shareholder value.Southern Cross is currently investing in companies that fit their investment criteria. They prefer to act as lead or co-lead in the early stages where they have experience that can help build value rapidly. They do not have a minimum investment amount, however, a typical initial investment will be $2 million to $5 million with an ability to invest more money in later rounds.
Show more...Investment focus
- Industry: Software, Manufacturing, Renewable Energy
- Stage:Series B, Series A
- Geography: United States, Australia, Singapore
Investor stats
- Total investments: 49
- Round size: Series A $2M–$5M; Series B $5M–$15M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $128M in 2012
Portfolio highlights
- Sunman — Sunman Energy is a technology company founded by a group of industry veterans delivering the future of Solar. Through the research and development of composite materials, Sunman has successfully commercialized the world’s first glass-free, lightweight and flexible Panel – eArc. Replacing glass completely, eArc brings solar power to markets andapplication scenarios that were previously impossible.
- Wave Computing — The future of high-tech in online casino is a bright one. For example, RFID technology will help casinos track and identify stolen chips. In addition, these systems can also predict player behavior and betting patterns. The latter are especially useful if a player is caught while he is trying to switch out his cards. These ... Read more
- Brisbane Materials Technology — Since 2005, we have helped thousands of people get the perfect domain name.
CP Ventures is a VC fund that invests internationally in early stage, highly scalable, breakthrough technology companies driven by the 4IR
Show more...Investment focus
- Industry: Software, Artificial Intelligence, Machine Learning
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States, India
Investor stats
- Total investments: 52
- Round size: Seed $364k–$4M; Pre-Seed $800k–$900k; Series A $5.1M–$12M
- Lead/follow: 46% lead, 54% follow
Portfolio highlights
- Anility — Embed financial health insights within your application using our world leading API service
- Ahura AI — Ahura AI, an EdTech startup using artificial intelligence to create personalized learning tools that replicate a 1-to-1 learning experience
- Ensuredit — ENSUREDIT enables and empowers end customers and Insurance Intermediaries with AI-based product platforms for transformational customer experience.
Venture capital investment can raise funds for your small business. Venture Capital Firms in the UK like Agronomics is a biotech venture capital firm which invest into the clean meat sector.
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Food Processing
- Stage:Seed, Series A, Series B
- Geography: United States, Finland, Australia
Investor stats
- Total investments: 33
- Round size: Seed $500k–$20M; Series A $6M–$20M
- Lead/follow: 48% lead, 52% follow
Portfolio highlights
- Meatable — Meatable is a food production company that produces real and guilt-free meat. With one cell, they are revolutionizing the meat industry's impact on climate change and animal welfare. At the same time they increase food security, without compromising the culinary experience of eating tasty, real meat. They aim to satisfy the world'sappetite for meat without harming people, animals, and the planet.It was founded in 2018 and is headquartered in Delft, South Holland, The Netherlands.
- Clean Food Group — Clean Food Group provides sustainable ‘CLEAN’ alternatives to these fats and oils, ranging from liquid oils like soybean to hard fats like palm oil, cocoa butter, and milk fat. Clean Food Group produces sustainable food ingredients that are better for our environment and health without compromising on teste or performance.
- HydGene Renewables — Our mission is to accelerate adoption of low carbon technology by providing an alternative green hydrogen solution.
Grand Challenges Canada is dedicated to supporting Bold Ideas with Big Impact® in global health. They are funded by the Government of Canada and they fund innovators in low- and middle-income countries (LMICs) and Canada. The bold ideas they support integrate science and technology, social and business innovation – they call this IntegratedInnovation®. They focus on bringing successful innovation to scale, catalyzing sustainability and impact. They have a determined focus on results, and on saving and improving lives.Grand Challenges Canada works closely with Canada’s International Development Research Centre (IDRC), the Canadian Institutes of Health Research (CIHR) and Global Affairs Canada to catalyze scale, sustainability and impact. Grand Challenges Canada takes an evidence-based approach to development innovation to save and improve lives in LMICs. They are a platform for development innovation in Maternal, Newborn and Child Health (MNCH) through their Saving Lives at Birth, Saving Brains and MNCH Stars in Global Health programs. They are also focused on helping the poorest and most vulnerable populations, for example those who suffer from mental illness.Since their launch in 2010, Grand Challenges Canada has supported a pipeline of over 700 projects in more than 80 countries. Their investments are producing results: Thousands of lives have been saved and over two hundred and eighty thousand lives have been improved, thus far. By 2030, these innovations have the potential to save hundreds of thousands of lives and improve millions of lives.
Show more...Investment focus
- Industry: Health Care, Medical Device, Biotechnology
- Stage:Grant, Seed, Debt Financing
- Geography: Canada, United States, Australia
Investor stats
- Total investments: 11
- Round size: Grant $100k–$3.3M; Debt Financing $726k–$2M
- Lead/follow: 55% lead, 45% follow
Portfolio highlights
- OmniVis — OmniVis is a technology company creating handheld devices to rapidly detect dangerous pathogens - saving food and saving lives.
- Nivi, Inc. — Nivi is the best digital health chatbot built for whatsapp and rooted in behavioral science. Nivi enables users to take charge of their own health and works with private and public agencies to driver better public health outcomes.
- Sensoreal — Sensoreal Inc. is a diagnostic device and service provider company. The company is developing a variety of biosensors, which can perform one-step immunoassays in low-cost, accurate and quantifiable manners. Sensoreal was founded in 2014, and is headquartered in Montreal, Canada.
Ellerston Capital is a specialist investment manager with a distinctive approach to portfolio construction and investment selection.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Seed, Series A
- Geography: Australia, Hong Kong, United Kingdom
Investor stats
- Total investments: 32
- Round size: Seed $850k–$16M; Series A $2.2M–$15M
- Lead/follow: 59% lead, 41% follow
Portfolio highlights
- Willed — Willed is an Australian online estate planning platform.
- BiomeBank — BiomeBank is a clinical stage biotechnology company with a mission to treat our microbiome and prevent disease by restoring gut microbial ecology.
- Internet 2.0 — Military Grade cyber security with core products Cloaking Firewall, Malcore and 5th Column
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.
Show more...Investment focus
- Industry: Science/Engineering, Biotechnology, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Australia
Investor stats
- Total investments: 98
- Round size: Series A $11M–$50M; Series B $9M–$93M; Series C $10M–$82M
- Lead/follow: 70% lead, 30% follow
Portfolio highlights
- Sound Agriculture — Sound Agriculture is creating a more agile and resilient food system with innovative on-demand crop solutions.
- Vestaron — Are you interested in biological peptides? If so, get in contact with Vestaron today. We will keep you informed about safer crop protection.
- EnPlusOne Biosciences — EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics.
Playford Capital is a venture capital arm of South Australian Government Financing Authority specializing in investments in start-ups, early venture, mid venture, late venture stages, and growth capital.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Signostics — Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it isanticipated the Signos will change the way healthcare professionals practice medicine.Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable pointâ€ofâ€care medical devices. The company launched its first product into the veterinarian market in January 2009 andgained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.
Driven by a mission to redefine food, Acre invests in companies creating systemic change in the food system to address the growing problems of human and environmental health. Acre makes venture-stage investments in highly disruptive platform business across the food value chain, with a particular focus on the agriculture, food tech and consumerverticals. Taken together, these investments have the ability to form the foundation of an integrated new approach to food system evolution.
Show more...Investment focus
- Industry: Food/Beverage, Gaming, Science/Engineering
- Stage:Series A, Series B, Series C
- Geography: United States, Brazil, Argentina
Investor stats
- Total investments: 34
- Round size: Series A $10M–$18M; Series B $15M–$40M; Series C $10M–$89M
- Lead/follow: 56% lead, 44% follow
- Last fund: May invest from a new fund soon — last raise in 2019
Portfolio highlights
- Planet FWD — Planet FWD is the leading carbon assessment platform for consumer brands.
- Loam Bio — Loam Bio is developing tech that allows for crops to be inoculated with symbiotic micro-organisms.
- People Science — People Science offers data collection technology and services for clinical research studies of alternative medicines and wellness interventions.
Right Click Capital - Australian Venture Capital Firm
Show more...Investment focus
- Industry: Software, IT, Data and Analytics
- Stage:Seed, Series A
- Geography: Australia, Singapore, United States
Investor stats
- Total investments: 53
- Round size: Seed $64k–$3M; Series A $3.1M–$15M
- Lead/follow: 25% lead, 75% follow
- Last fund: May invest from a new fund soon — last raise in 2017
Portfolio highlights
- Tribu — Here at tribu we aim to make running an MSP stress-free and simple. Remove complexity and repetitive shackles to give you the freedom in business so that you can have freedom in life.
- Cydarm — A case management platform that enables cybersecurity operations teams to collaborate, integrate, and respond with ease.
- Reejig — At Reejig, we believe in zero wasted potential in people and in business – and that starts with harnessing the skills you have within your organisation. Our workforce intelligence platform provides 100% visibility of your people’s skills, potential, passions and experiences, creating a powerful central nervous system for all talent decisions.Powered by the world’s first independently audited Ethical Talent AI engine, Reejig generates the intelligence to instantly fill roles, track retention risks, mobilise talent to opportunities, pivot talent for reskilling and much more. Plus, we give you the power to ‘nudge’ people to new career opportunities, taking your engagement with internal and external talent to the next level. Put simply, we make workforce agility a reality.Reejig is trusted and used by some of the largest and most complex organisations including Woolworths, KPMG, NSW Government, John Holland, MYOB and UTS, and together we are creating a world where everyone can reach their full potential at work. It’s what we call zero-wasted potential in people and in business.
HESTA Super Fund is the Australian industry superannuation fund for people working in health and community services. Become a member today.
Show more...Investment focus
- Industry: Sensor, Medical, Aerospace
- Stage:Series A, Series B, Series C
- Geography: Australia
Investor stats
- Total investments: 4
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Baraja — Baraja is a deep technology company that has reinvented LiDAR for self-driving vehicles. Our patented platform, Spectrum-Scan™, takes a fundamentally different approach to LiDAR. Instead of relying on fragile moving parts and oscillating mirrors, we simply refract light through a prism to scan the environment. This patented method allows us todeliver unprecedented range, precision, and reliability in even the most extreme environments.
- Citadel Group Ltd — Citadel develops and delivers technology and education solutions to state and federal government departments, and the private sector in Australia. The company operates through Technology and Education segments. The Technology segment sells professional and managed services to government agencies and private enterprises. Its services includestrategic advice, program management, acquisition support, and quality assurance services through consulting, contracting, and placement mechanisms; technology and integration services; and software solutions, products, and managed services for digital health, diagnostic laboratories, and clinical applications. The Education segment delivers a range of nationally-accredited business qualifications that enable students to articulate into second year university or to gain practical skills for employment.
- Gilmour Space Technologies — Gilmour Space is a rocket company in Australia that is developing and launching low-cost small satellite launch vehicles. All orbits, all planets: https://www.gspacetech.com
AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Togetherwith its wholly-owned subsidiary, Pharmacyclics, AbbVie employs ~29,000 people worldwide and markets medicines in more than 175 countries.
Show more...Investment focus
- Industry: Biotechnology, Science/Engineering, Health Care
- Stage:Series A, Series B, Series C
- Geography: United States, China, Italy
Investor stats
- Total investments: 46
- Round size: Series A $6M–$50M; Series B $12M–$100M; Series C $60M–$75M
- Lead/follow: 17% lead, 83% follow
Portfolio highlights
- Nitrase Therapeutics — Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications.
- Quanta Therapeutics — Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA.
- AmbAgon Therapeutics — AmbAgon Therapeutics is a developer of cancer molecule therapeutics. The company offers research of a small molecule that augments a tumor-suppressing protein. AmbAgon Therapeutics was founded by Christian Ottmann, Lucas Brunsveld, and Michelle Arkin.
Alloy Ventures is an early stage venture capital firm that invests in the areas of life sciences, information technology, and cleantech.
Show more...Investment focus
- Industry: Software, Science/Engineering, Hardware
- Stage:Series C, Series B, Series D
- Geography: United States, Canada, Australia
Investor stats
- Total investments: 122
- Round size: Series B $8M–$29M; Series C $4.9M–$25M; Series D $5.3M–$50M
- Lead/follow: 17% lead, 83% follow
- Last fund: May invest from a new fund soon — raised $375M in 2008
Portfolio highlights
- Agari — Agari is the Trusted Email Identity Company™, protecting brands and people from devastating phishing and socially-engineered attacks. Using applied data science and a diverse set of signals, Agari protects the workforce from inbound business email compromise, supply chain fraud, spear phishing, and account takeover-based attacks, reducing businessrisk and restoring trust to the inbox. Agari also prevents spoofing of outbound email from the enterprise to customers, increasing deliverability and preserving brand integrity.
- AEGEA Medical — Mara, a safe and effective in-office treatment that uses natural water vapor to reduce heavy menstrual bleeding in premenopausal women
- Restoration Robotics — Restoration Robotics is a privately held medical device company, is dedicated to revolutionizing the field of hair transplantation by developing and commercializing a state-of-the-art image-guided system (ARTAS™ System) that enables follicular unit extraction.
Terra Rossa Capital Pty Ltd operates as a venture capital fund. The Company invests in life science companies. Terra Rossa Capital serves clients in Australia.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical Device
- Stage:Series A, Series B
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Signostics — Signostics produces Biotech medical devices. Their flagship product, Signos, allows healthcare professionals to use ultrasound in their clinical practice. It offers ultrasound platform technology that clinicians can place in their pocket or wear around their neck like a stethoscope. Just as handheld devices transformed the business world, it isanticipated the Signos will change the way healthcare professionals practice medicine.Signostics was established in Adelaide, Australia in 2005 and expanded into the U.S. in 2008, dedicated to developing fast and affordable pointâ€ofâ€care medical devices. The company launched its first product into the veterinarian market in January 2009 andgained regulatory approvals to enter the human medical device market for the United States, Europe, and Australia in May 2009. Signostics has offices in Palo Alto, California and Adelaide, South Australia.
Nanyang Ventures invests with the aim of building listable companies. Company spokesman John Mulquiney said the Genetic Solutions management team had been successful at commercialising the company's technology.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Science/Engineering
- Stage:Series A
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- QRxPharma — QRxPharma is an Australian-based, commercial-stage specialty pharmaceutical company focused on the development and commercialization of new pain management and abuse prevention productsBased on a development strategy that focuses on enhancing the clinical utility of currently approved compounds as well as bringing new products to market, thecompany's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes.In Q4 2013, the Company plans to refile with the US Food and Drug Administration a New Drug Application for its lead product candidate, immediate release MOXDUO®, for the treatment of acute pain. QRxPharma has entered into strategic agreements with Actavis Inc., Paladin Labs Inc. and Aspen Group for the commercialisation of immediate release MOXDUO in the US, Canada, Australia (including New Zealand and Oceania) and South Africa.The Company's clinical pipeline includes an intravenous (IV) and controlled release (CR) formulation of MOXDUO. QRxPharma is also collaborating with Aesica Formulation Development Limited, for the worldwide promotion of QRxPharma's proprietary Stealth Beadlets™ abuse deterrence technology.
CaraMed Capital is a deep-health tech venture capital fund.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Powerhouse Ventures backs entrepreneurs building the digital infrastructure for rapid decarbonization.
Show more...Investment focus
- Industry: Software, Energy, Solar
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Australia, United Kingdom
Investor stats
- Total investments: 41
- Round size: Seed $726k–$3.5M; Series A $8.2M–$30M
- Lead/follow: 10% lead, 90% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Tyba — Tyba provides end-to-end modeling of standalone and hybrid storage projects from early-stage development through operations, giving your business the edge to build and operate the best projects faster and more profitably.
- Axiom Cloud — Axiom Cloud Inc. uses AI to solve the biggest energy and maintenance problems plaguing the underserved commercial cooling/refrigeration industry ($120B/year in the US alone). Our first target customer segment is retail grocery. Customers pay an initial setup fee to install/configure the IoT platform onsite, along with recurring SaaSfees for one or more cloud-based software apps that run on the IoT platform.
- Granular Energy — Granular Energy provides solutions for managing and trading clean energy. Our tools have been developed to support the recent emergence of 24/7 time-stamped energy certificates as well as traditional "annual" certificates.
Founded by Steve Baxter, Transition Level Investments provides equity capital and operational expertise across Seed and Series A rounds to Australian companies. Our team focuses on a company-growth approach, adding value by assisting founders to build their expertise, expand their team, build product, scale locally and globally to position for asuccessful exit. We have a track record of identifying investment opportunities in the Australian market and helping enable global growth.
Show more...Investment focus
- Industry: Software, Financial, IT
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia, United States
Investor stats
- Total investments: 17
- Round size: Seed $835k–$2.4M; Pre-Seed $60k–$1.5M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Kapiche — Instant insights. No set up or coding. The Kapiche feedback analytics platform helps you ingest and analyze mountains of customer feedback in minutes.
- FloodMapp — Enhance operational efficiency, lead time, situational awareness and decision making using FloodMapp rapid flood mapping software.
- Chipper Cash — Join over 5 million people securely sending and receiving money with Chipper Cash. Great app to send and receive money across a number of countries, highly recommended as a money transfer alternative.
Alta Partners is a leading healthcare and life sciences venture capital firm, helping entrepreneurs build high-impact companies since 1996.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Science/Engineering
- Stage:Series C, Series B
Investor stats
- Round size: Series B $16M–$58M; Series C $10M–$109M
- Lead/follow: 23% lead, 77% follow
- Last fund: May invest from a new fund soon — last raise in 2021
A grant program offered by AusIndustry as part of the Australian Government’s National Innovation and Science Agenda
Show more...Investment focus
- Industry: Software, Mining, Hardware
- Stage:Grant, Pre-Seed
- Geography: Australia
Investor stats
- Total investments: 2
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Neuromersiv — Neuromersiv empowers stroke and brain injury survivors with clinically designed virtual reality-based neurological rehabilitation solutions.
- Tiny Bright Things — Melbourne-based company Tiny Bright Things was cofounded in 2020 by long-time research collaborators Ray Dagastine and Chris Bolton. We invented Halo microscopy to transform the way researchers and manufacturers look at small or transparent things. This helps manufacturers in areas like agrichemicals and pharmaceuticals (where the size and shape ofpowders are critical) and researchers at every stage of discovery— particularly in nanotechnology (where samples are especially tiny) and life sciences (where samples are often also transparent).
Founded in 1996, GBS invests in young businesses developing and commercialising products which, when combined with the right management and finance, will make a significant difference to patients' lives and deliver financial returns for their investors. Their areas of particular interest and expertise include human healthcare, biotechnologyproduct development and life science start-ups. In particular, recent investments have included biological or small molecule therapeutics, medical devices and diagnostics.GBS invests in private or public companies whether at start-up or later stages of company development. Their investors include major Australian superannuation funds.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Science/Engineering
- Stage:Series A, Series C, Series B
Investor stats
- Round size: Series A $2.1M–$9M; Series B $9.3M–$20M; Series C $3M–$55M
- Lead/follow: 20% lead, 80% follow
We Invest in the Circular Economy, a New Economic Model Focused on a Profitable and Sustainable Future.
Show more...Investment focus
- Industry: Recycling, Supply Chain Management, Artificial Intelligence
- Stage:Series A, Seed
- Geography: United States, United Kingdom, Chile
Investor stats
- Total investments: 29
- Round size: Seed $3.2M–$6M; Series A $6M–$16M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Earthodic — Earthodic is an Australian materials science company creating functional biobased coatings. Paperbarc by Earthodic is a biobased water-resistant coating for pulped or paper products. It has better water-resistance than wax coatings, more sustainable and circular than plastic coatings. Repulpable. Re
- EcoSpirits — The World's first low carbon, low waste spirits distribution technology. Join the revolution. End single use glass.
- Solarcycle — We offer solar asset owners a low-cost, eco-friendly, comprehensive process for retiring solar panels and repurposing them for new uses.
Catherine Lacavera is the VP, Legal at Google.
Show more...Investment focus
- Industry: Medical, Health Care, Biotechnology
- Stage:Seed, Pre-Seed
- Geography: Canada, Australia
Investor stats
- Total investments: 2
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Skritswap — skritswap software reduces the reading level of information.
- HealthMatch — HealthMatch is a medical technology company that applies machine learning and artificial intelligence to clinical data to save lives.We aim to dramatically accelerate patient recruitment to clinical trials, and progress life-saving cures onto the market faster than existing practices allow.For clinicians and patients, there is a real struggleto identify and find appropriate trials, particularly where the criteria relating to each trial is inconsistently articulated. HealthMatch encodes qualifying questions relating to each patients condition. The platform matches responses to its trial dataset, and confirms only the correct-match trials for that patient — thereby streamlining the identification of suitable trials and facilitating a patient’s application to those trials.With Ai and software at the core, HealthMatch delivers a radically simple product to match patients with drug trials, backed by an execution approach to data that is deceptively complex to achieve and replicate. In doing so, HealthMatch is dramatically changing an industry that has essentially not moved beyond telephones and excel spreadsheets.
Daniel Petre is the Founder of StartGiving. He was a Founding Chairman and Board Member at Ninemsn. He attended the University of Sydney.
Show more...Investment focus
- Industry: SaaS, Software, Banking
- Stage:Seed, Pre-Seed, Series A
- Geography: Australia
Investor stats
- Total investments: 5
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Ento — Manage compliance, increase revenue and reduce labour costs with Ento's single, HR, workforce management and onboarding software.
- Psylo — Psylo is an Australia-based psychedelic biotech business focusing on Psychedelic-inspired medicine to treat mental illness.
- Kismet — Find the best disability or healthcare service to support your journey
The inaugural fund will seek to identify and invest in opportunities to supplement growth in the core business and advance the development of adjacent technologies for the future.
Show more...Investment focus
- Industry: Sensor, Medical, Wearables
- Geography: Australia
Investor stats
- Total investments: 1
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Nutromics — Nutromics is a MedTech company revolutionising healthcare through continuous real time molecular monitoring. Our Smart Patch biosensor platform will solve some of the biggest healthcare challenges we face today in the fields of chronic disease prevention, chronic disease management, acute diseases and Therapeutic Drug Monitoring.
Maropost Ventures is a leading private equity firm that invests in people and their companies from the earliest days through all stages of Growth. SpaceX, Compono, Pressa and Lyres make up some of their first investments.
Show more...Investment focus
- Industry: Science/Engineering, Commerce/Shopping, Data and Analytics
- Stage:Seed, Series A, Secondary Market
- Geography: United States, Australia, Sweden
Investor stats
- Total investments: 15
- Round size: Seed $1.1M–$10M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Radinn — Radinn offers wakeboarders, kiteboarders, and surfers with water sport products. The company’s first product, Wakejet, is an electrically powered wakeboard built using lithium-ion battery technology. Its speed is controlled by a wireless and water proof remote.Radinn is headquartered in Malmö, Sweden with presence in Florida, United States andAdmiralty, Hong Kong.
- Detected — Detected fills the critical KYB gap in the payments technology stack. Customers can complete Know Your Business requirements within their own CRM via API.
- Lyre's Spirit Co — Many years in the making, Lyre’s exquisite range of lovingly crafted alcohol-free, classic spirits was borne from a quest to make the impossible possible. To provide an alternative to those who don’t wish to imbibe alcohol, but still wish to enjoy the mirth, merriment and social intercourse of an evening soiree or shindig. But this is not justany alternative. Every Lyre’s spirit looks, tastes and sashays around the palate just like the original. And yet, the absence of giggle juice enables revellers to remain clear-headed, of good cheer and in fine fettle to pursue whatever tickles their fancy the following day. Lyre’s – the finest range of non-alcoholic classic spirits the world has ever seen.
FAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Australia investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 48,091 investors investing in Australia Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!